The FDA has made a request to all makers of Gadolinium-based contrast agents to incorporate a warning on the product label. “These contrast agents are used to enhance the quality of magnetic resonance imaging (MRI) and can place patients at risk for developing a potentially fatal disease known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD). Individuals who develop these diseases could have a thickening of their skin and/or other organs, which as a result, can harm their ability to move their body and extended joints and can cause serious pain as well as death. Investigations are evaluating the “Gadolinium-based contrast agents involving patients who have developed nephrogenic systemic fibrosis or Nephrogenic Fibrosing Dermopathy”.
- January 12, 2010
- Business/Corporate Law / Health News / News / Personal Injury
- 0 Comments
Tags: Damages, Dangerous Drugs, Disease, FDA, Food and Drug Administration, Gadolinium-Based Contrast Agents, Law, Lawsuit, Legal, MRI, Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis, News, NFD, NSF, personal injury, Products Liability, Warning Label, Wrongful Death